Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 2
2005 2
2006 1
2007 1
2012 1
2013 2
2014 3
2015 5
2016 5
2017 2
2018 10
2019 4
2020 10
2021 13
2022 9
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer.
Tozuka T, Noro R, Yoshida K, Takahashi S, Hirao M, Matsuda K, Kato Y, Nakamichi S, Takeuchi S, Matsumoto M, Miyanaga A, Kunugi S, Honda K, Adachi J, Seike M. Tozuka T, et al. Among authors: matsumoto m. JTO Clin Res Rep. 2024 Mar 21;5(4):100668. doi: 10.1016/j.jtocrr.2024.100668. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38646155 Free PMC article.
Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia.
Isobe K, Nakamura Y, Sakamoto S, Tomii K, Takimoto T, Miyazaki Y, Matsumoto M, Sugino K, Ichikado K, Moriguchi S, Yamaguchi K, Baba T, Ozasa H, Igata F, Anabuki K, Homma S, Date H, Suda T, Kishi K. Isobe K, et al. Among authors: matsumoto m. ERJ Open Res. 2024 Mar 4;10(2):00981-2023. doi: 10.1183/23120541.00981-2023. eCollection 2024 Mar. ERJ Open Res. 2024. PMID: 38444654 Free PMC article.
Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC.
Terashima Y, Matsumoto M, Iida H, Takashima S, Fukuizumi A, Takeuchi S, Miyanaga A, Terasaki Y, Kasahara K, Seike M. Terashima Y, et al. Among authors: matsumoto m. JTO Clin Res Rep. 2023 Sep 21;4(11):100578. doi: 10.1016/j.jtocrr.2023.100578. eCollection 2023 Nov. JTO Clin Res Rep. 2023. PMID: 37885809 Free PMC article.
Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report.
Iso H, Miyanaga A, Kadoma N, Shinbu K, Tozuka T, Murata A, Nishima S, Sato Y, Nakamichi S, Matsumoto M, Noro R, Terasaki Y, Kubota K, Seike M. Iso H, et al. Among authors: matsumoto m. Onco Targets Ther. 2023 Jun 23;16:465-470. doi: 10.2147/OTT.S404035. eCollection 2023. Onco Targets Ther. 2023. PMID: 37384219 Free PMC article.
77 results